Pediatric Neurology
Volume 28, Issue 1 , Pages 37-41 , January 2003

Oxcarbazepine in the treatment of childhood epilepsy

  • Gul Serdaroglu, MD

      Affiliations

    • Department of Pediatrics, Division of Child Neurology, Ege University Faculty of Medicine, Izmir, Turkey
    • Corresponding Author InformationCommunications should be addressed to: Dr. Serdaroglu; Department of Pediatrics; Ege University Faculty of Medicine; Bornova-Izmir, Turkey.
    • ,
  • Semra Kurul, MD

      Affiliations

    • Department of Pediatrics, Division of Child Neurology, Eylül University Faculty of Medicine, Eylül University Faculty of Medicine, Izmir, Turkey
    • ,
  • Sarenur Tutuncuoglu, MD

      Affiliations

    • Department of Pediatrics, Division of Child Neurology, Ege University Faculty of Medicine, Izmir, Turkey
    • ,
  • Eray Dirik, MD

      Affiliations

    • Department of Pediatrics, Division of Child Neurology, Ege University Faculty of Medicine, Izmir, Turkey
    • ,
  • Berrak Sarioglu, MD

      Affiliations

    • Department of Pediatrics, Division of Child Neurology, Ege University Faculty of Medicine, Izmir, Turkey

Received 21 March 2002 ,Accepted 27 June 2002.

References 

  1. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994;35(Suppl 3):S10–13
  2. Wamil AW, Schmutz M, Portet C, Feldmann KF, McLean MJ. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol. 1994;271:301–308
  3. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels (Targets of antiepileptic drug therapy?). Epilepsia. 1997;38:959–965
  4. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia. 1997;38(Suppl):21–31
  5. Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate and other new antiepileptic drugs. Epilepsia. 1995;36:105–114
  6. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med. 1996;334:1523–1590
  7. Commission on classification and terminology of the International League Against Epilepsy. A revised proposal for the classification of epilepsy and epileptic syndromes. Epilepsia 1989;30:268–78
  8. Van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsia Res. 1994;19:79–85
  9. Wellington K, Goa KL. Oxcarbazepine (An update of its efficacy in the management of epilepsy). CNS Drugs. 2001;15:137–163
  10. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol. 1997;12:496–498
  11. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res. 1989;3:70–76
  12. Beydoun A, Sachdeo RC, Rosenfeld WE, et al.  Oxcarbazepine monotherapy for partial-onset seizures. A multicenter, double-blind, clinical trial. Neurology. 2000;54:2245–2251
  13. Sachdeo R, Beydoun A, Schachter S, et al.  Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57:864–871
  14. Schachter SC, Vazquez B, Fisher RS, et al.  Oxcarbazepine. Double blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732–737
  15. Isojarvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia. 1994;35:1217–1220
  16. Papacostas SS. Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities. J Child Neurol. 2000;15:138–140
  17. Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):37–46
  18. Borusiak P, Merker E, Holert N, Boenigk E. Oxcarbazepine treatment of childhood epilepsy (A survey of 46 children and adolescents). J Epilepsy. 1998;11:355–360

PII: S0887-8994(02)00467-8

doi: 10.1016/S0887-8994(02)00467-8

Pediatric Neurology
Volume 28, Issue 1 , Pages 37-41 , January 2003

Article Tools

* Image Usage & Resolution